Dizal's Lung Cancer Pipeline Takes Center Stage at ASCO 2026

SHANGHAI – April 21, 2026 – Biopharmaceutical firm Dizal is poised to make a significant impact at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, with a slate of presentations highlighting major advancements across its non-small cell lung cancer (NSCLC) portfolio. The company will unveil pivotal data, including late-breaking results for its drug ZEGFROVY®, that could reshape treatment standards for some of the most challenging forms of the disease.

The presentations, scheduled for late May in Chicago, feature two oral sessions and a poster, spotlighting a multi-pronged strategy that addresses initial treatment, acquired resistance, and the enhancement of immunotherapy. This comprehensive approach underscores Dizal's emergence as a key innovator in the global fight against lung cancer.

A New Standard for a Notorious Mutation

The most anticipated data comes from the multinational Phase 3 WU-KONG28 study, which has been granted a prestigious Late-Breaking Abstract (LBA) oral presentation. The study evaluates ZEGFROVY® (sunvozertinib) as a first-line monotherapy for patients with advanced NSCLC harboring an epidermal growth factor receptor (EGFR) exon 20 insertion (exon20ins) mutation.

For years, this specific mutation has been a frustrating target for oncologists. Unlike more common EGFR mutations, exon20ins has been notoriously resistant to earlier generations of EGFR tyrosine kinase inhibitors (TKIs), leaving patients with few options beyond platinum-based chemotherapy. While newer combination therapies have emerged, the search for a highly effective, well-tolerated oral monotherapy has remained a critical unmet need.

Dizal has announced that the WU-KONG28 trial successfully met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for sunvozertinib compared to standard chemotherapy. This result suggests that patients could soon have a powerful, targeted, chemotherapy-free oral option right from diagnosis.

"The new data to be reported at ASCO 2026 show significant progress we have made with our non-small cell lung cancer (NSCLC) pipeline," said Dr. Xiaolin Zhang, CEO of Dizal. "We are especially happy to report that WU-KONG28 met its primary endpoint. EGFR exon20ins is a tough target, and several compounds have failed in clinical studies. With this positive study, Zegfrovy further demonstrates its potential as the treatment of choice for newly diagnosed lung cancer patients with EGFR exon20ins mutation."

The selection for an LBA presentation, a slot reserved for data deemed to have a high impact on clinical practice, signals the medical community's keen interest in the full results, which will be presented by Prof. John Heymach on May 29.

Tackling the Next Wall of Resistance

While ZEGFROVY® targets a specific challenge in newly diagnosed patients, another of Dizal's assets, DZD6008, is designed to solve a problem that arises later in the treatment journey. Many patients with common EGFR mutations benefit greatly from third-generation TKIs like osimertinib. However, the cancer often evolves, developing new mutations that cause the treatment to fail.

One of the most significant of these resistance mechanisms is the EGFR C797X mutation. Currently, there are no approved targeted therapies for patients whose cancer develops this mutation, forcing a return to less effective chemotherapy.

Dizal's DZD6008, a novel fourth-generation EGFR TKI, was specifically designed to overcome this hurdle. Data from its Phase 1/2 studies, to be presented in a rapid oral session at ASCO, will shed light on its efficacy in this heavily pretreated patient population. Preclinical models have shown DZD6008's potent activity against a wide range of resistance mutations, including the challenging triple mutations that can render other drugs ineffective.

Crucially, DZD6008 was engineered for full penetration of the blood-brain barrier (BBB). This is a vital feature, as brain metastases are a frequent and devastating complication of NSCLC, affecting a significant percentage of patients. A drug that can effectively treat both the cancer in the body and in the brain could provide a substantial clinical benefit and address a major cause of disease progression and mortality.

Reimagining Immunotherapy for Broader Impact

Beyond its focus on targeted therapies for EGFR-mutated cancers, Dizal is also exploring innovative ways to improve outcomes for a broader group of NSCLC patients. The company will present a poster on its third asset, golidocitinib, a Janus kinase 1 (JAK1) inhibitor being studied in combination with an anti-PD-1 antibody.

This trial focuses on NSCLC patients without known driver mutations who have progressed on prior immunotherapy regimens. While checkpoint inhibitors (like anti-PD-1 antibodies) have revolutionized cancer care, many patients either do not respond or eventually become resistant. Scientists believe this resistance is partly driven by an immunosuppressive tumor microenvironment.

The rationale behind the golidocitinib combination is to use the JAK1 inhibitor to modulate this environment, essentially "reawakening" the immune system's ability to attack the cancer. Preclinical data suggests that inhibiting JAK1 can rescue exhausted T-cells and create a more favorable setting for anti-PD-1 therapy to work. Golidocitinib is already the world's first approved JAK1 inhibitor for a type of lymphoma, providing a foundation of clinical experience for its expansion into lung cancer. This investigation represents a forward-thinking strategy to salvage or enhance the efficacy of one of the most important classes of cancer drugs.

Together, the data from these three distinct assets paint a picture of a company building a comprehensive and strategic NSCLC franchise. From providing a potential new first-line standard of care for a difficult mutation, to developing a solution for acquired resistance, to finding new ways to boost immunotherapy, Dizal's ASCO showcase demonstrates a deep commitment to addressing the full spectrum of challenges faced by lung cancer patients today. The full data presented in Chicago will be closely watched by clinicians and researchers eager for new tools to combat this complex disease.